Axsome Therapeutics stock hits all-time high at 236.84 USD
Axsome Therapeutics Inc. (AXSM) stock reached an all-time high of $235, trading near its 52-week high of $235.91, marking a significant 124% increase over the past year with 64% revenue growth. Despite this, the company reported a net loss of $1.26 per share and revenue slightly below expectations for Q1 2026, though investor sentiment remains positive. InvestingPro indicates the stock is trading near its Fair Value, and the company remains unprofitable over the past twelve months.
AXSM: June launch of new Alzheimer's agitation drug, expanded sales force, and robust pipeline progress
Axsome Therapeutics (AXSM) is set to launch a new FDA-approved Alzheimer's agitation treatment in June, supported by a doubled sales force and strong payer access. The company also continues to see growth in its MDD and migraine franchises and is advancing multiple pipeline programs in sleep and neuropsychiatry. This information is based on an RBC Capital Markets Global Healthcare Conference audio transcript.
Axsome Therapeutics (AXSM) price target increased by 18.66% to 272.70
This article reports that the price target for Axsome Therapeutics (AXSM) has been increased by 18.66%, bringing it to $272.70. No further details are provided regarding the reasons for this adjustment or the analysts responsible.
Axsome Therapeutics (AXSM) price target increased by 18.66% to 272.70
This article reports that Axsome Therapeutics (AXSM) has received an updated price target. The new target is $272.70, representing an 18.66% increase from previous estimates. This adjustment indicates a positive outlook from analysts regarding the company's future stock performance.
Axsome Therapeutics (AXSM) price target increased by 18.66% to 272.70
The price target for Axsome Therapeutics (AXSM) has been increased by 18.66%. The new price target is set at $272.70. This update indicates a significant positive adjustment in analysts' outlook for the company's stock.
Axsome Therapeutics (AXSM) price target increased by 18.66% to 272.70
This article reports that the price target for Axsome Therapeutics (AXSM) has been increased by 18.66%. The new price target is set at $272.70.
A Look At Axsome Therapeutics (AXSM) Valuation After AUVELITY Alzheimer’s Agitation Launch Plans And Earnings Update
Axsome Therapeutics (AXSM) is gaining attention after announcing plans to launch AUVELITY for Alzheimer’s disease agitation in June, supported by an expanded sales force and anticipated broad Medicare Part D coverage. The stock has seen significant momentum, including a 26.11% return over 30 days and 116.63% over one year, and is currently trading at a 16% discount to the average analyst price target. While some narratives suggest it's undervalued with a fair value of $266.94, others point to its rich P/S ratio (16.9x) compared to industry averages, raising questions about whether its growth can justify the premium.
Axsome Therapeutics stock hits all-time high at 234.57 USD
Axsome Therapeutics Inc. (AXSM) stock has reached an all-time high of $234.57 USD, driven by a 123.94% increase over the past year and a 64% revenue surge in Q1 2026, totaling $708 million. Despite a significant earnings miss and slightly lower-than-expected revenue in Q1 2026, investor optimism remains evident. The company maintains a strong gross profit margin of 93% and has a market capitalization of $12 billion, with analysts setting price targets between $200 and $329.
Axsome Therapeutics (AXSM) Is Up 5.7% After AUVELITY Alzheimer’s Agitation Approval And Launch Push - Has The Bull Case Changed?
Axsome Therapeutics recently reported strong first-quarter 2026 results and received FDA approval for AUVELITY to treat agitation associated with Alzheimer’s disease. This label expansion creates a new market opportunity, supported by an enlarged sales force and broad Medicare Part D coverage, which could significantly impact the company's investment narrative. The article questions whether these developments, especially the new indication for AUVELITY, will alter the bull case for the company.
Axsome Therapeutics stock hits all-time high at 234.57 USD By Investing.com
Axsome Therapeutics Inc. stock reached an all-time high of $234.57, reflecting a 123.94% increase over the past year and a market capitalization of $12 billion. Despite a significant earnings miss in Q1 2026, with a net loss of $1.26 per share, investor optimism persists. The company's revenue surged 64% over the last twelve months to $708 million, maintaining a gross profit margin of 93%.
Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions
Axsome Therapeutics received FDA approval for its drug AUVELITY for agitation associated with dementia due to Alzheimer's disease, marking it as the first approved treatment for this indication. This creates a new commercial opportunity for Axsome, with the stock currently trading significantly below analyst targets and its estimated fair value. Investors are advised to monitor prescription uptake for this new use and updates to analyst price targets.
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch
Axsome Therapeutics is preparing for a June launch of AUVELITY for Alzheimer’s disease agitation, significantly expanding its sales force to 630 representatives and leveraging broad payer access. The company highlights AUVELITY's differentiated clinical profile, including rapid efficacy and a favorable safety label, to target both the new indication and major depressive disorder. Axsome anticipates strong Medicare Part D coverage for Alzheimer’s agitation prescriptions and is also investing in primary care and direct-to-consumer marketing to support continued growth for AUVELITY and other pipeline assets like SYMBRAVO and SUNOSI.
Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions
Axsome Therapeutics received FDA approval for AUVELITY to treat agitation associated with Alzheimer’s disease, making it the first approved treatment for this indication. The approval introduces a new commercial opportunity for Axsome and has been met with significant investor interest, with the stock seeing substantial gains over the past year. While the stock trades below analyst targets and an estimated fair value, investors will be monitoring prescription uptake and future market positioning.
Axsome’s AUVELITY Alzheimer’s Approval Sparks Valuation And Growth Questions
Axsome Therapeutics (NasdaqGM:AXSM) has received U.S. FDA approval for AUVELITY to treat agitation associated with dementia due to Alzheimer’s disease, marking it as the first approved treatment for this indication. This creates a new commercial opportunity for Axsome, with the stock currently trading at $216.47 and showing strong recent momentum. Investors are advised to monitor prescription uptake, analyst target updates, and the company's P/E ratio compared to the industry average.
Trading the Move, Not the Narrative: (AXSM) Edition
This article analyzes Axsome Therapeutics Inc. (NASDAQ: AXSM) using AI models, focusing on trading strategies and risk management. It identifies weak near-term sentiment but strong mid and long-term support signals, providing specific entry, target, and stop-loss points for position, momentum breakout, and risk hedging strategies. The analysis emphasizes trading based on AI-generated signals rather than market narratives.
Earnings call transcript: Axsome Therapeutics Q1 2026 reveals mixed results
Axsome Therapeutics reported mixed financial results for Q1 2026, with a net loss of $1.26 per share exceeding forecasts, but revenue reaching $191.2 million, slightly below expectations yet showing 57% year-over-year growth. The company's stock rose 8% pre-market, reflecting investor optimism driven by strong product sales, particularly AUVELITY, and its recent FDA approval for Alzheimer’s disease agitation. Axsome has updated its peak annual sales outlook for AUVELITY to at least $8 billion.
Axsome Q1 2026 slides: 57% revenue surge, $18B peak sales target
Axsome Therapeutics reported a robust 57% year-over-year revenue growth in Q1 2026, reaching $191.2 million, primarily driven by its flagship depression treatment AUVELITY. The company's stock rose 8% pre-market following the FDA approval of AUVELITY for a second indication (agitation associated with dementia due to Alzheimer’s disease) and its ambitious target of over $18 billion in peak sales potential across its portfolio. Despite a wider-than-expected net loss, Axsome remains confident in its growth trajectory, supported by pipeline advancements and strong patent protection.
Earnings call transcript: Axsome Therapeutics Q1 2026 reveals mixed results
Axsome Therapeutics Inc. reported mixed financial results for Q1 2026, with revenue of $191.2 million, slightly below expectations, but an earnings per share miss at -$1.26. Despite the earnings shortfall, the stock saw an 8% increase in pre-market trading, driven by strong product sales and positive investor sentiment regarding AUVELITY's potential, especially with its recent FDA approval for Alzheimer’s disease agitation. The company projects AUVELITY to reach at least $8 billion in annual peak sales and maintains a strong cash balance to fund operations into cash flow positivity.
Axsome Therapeutics (NasdaqGM:AXSM) Stock Forecast & Analyst Predictions
Axsome Therapeutics (AXSM) is projected to grow earnings by 57.3% and revenue by 31.7% annually, with a forecast return on equity of 65.9% in three years. Recent updates include FDA approval for Auvelity in Alzheimer's agitation, with a peak sales target of US$8 billion, and several ongoing late-stage pipeline developments. Despite strong revenue growth and pipeline potential, some analysts express concerns about profitability, high marketing costs, and competitive pressures, with the company’s breakeven date pushed back to 2026.
Axsome Therapeutics Recognizes Mental Health Month
Axsome Therapeutics announced its support for Mental Health Month, highlighting the prevalence of mental health conditions like Major Depressive Disorder and promoting resources from organizations like Mental Health America, ADAA, and NAMI. The company emphasizes its mission to develop transformative medicines for CNS disorders and encourages awareness and support for those affected by mental illness.
Principal Financial Group Inc. Lowers Holdings in Axsome Therapeutics, Inc. $AXSM
Principal Financial Group Inc. has reduced its stake in Axsome Therapeutics by 1.4% in the fourth quarter of 2025, now holding 363,114 shares valued at $66.32 million. This reduction comes amid mixed quarterly results for Axsome, with revenue growth driven by AUVELITY and SUNOSI, but a wider-than-expected GAAP EPS loss, raising profitability concerns. Insider selling also notably increased, with 72,628 shares sold over the last three months, though institutional investors still own a significant 81.49% of the company.
Axsome Therapeutics Recognizes Mental Health Month
Axsome Therapeutics is supporting Mental Health Month with the theme "More Good Days Together," highlighting resources for individuals and families affected by mental health conditions. The company's mission is to develop transformative medicines for CNS disorders, including major depressive disorder, which affects millions. Axsome is promoting non-profit organizations like Mental Health America, ADAA, and NAMI, and the 988 Suicide & Crisis Lifeline to raise awareness and provide support.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$270
Axsome Therapeutics' recent first-quarter results show revenues in line with expectations at US$191 million, but statutory losses increased to US$1.26 per share. Despite the increased forecast for losses next year, analysts have lifted their average price target to US$270, indicating a belief in potential long-term intrinsic value improvement. The company is projected to achieve significant revenue growth of 39% in 2026, outpacing the broader industry.
Axsome Therapeutics Recognizes Mental Health Month
Axsome Therapeutics is supporting Mental Health Month, focusing on the "More Good Days Together" theme, by sharing resources for individuals and families affected by mental health conditions. The company highlights the high prevalence of mental illness, particularly major depressive disorder, in the U.S., and promotes non-profit organizations like Mental Health America, ADAA, and NAMI-NYC, along with the 988 Suicide & Crisis Lifeline. Axsome's mission is to develop transformative medicines for CNS disorders, aiming to improve brain health for millions.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Released Earnings Last Week And Analysts Lifted Their Price Target To US$270
Axsome Therapeutics recently released its first-quarter results, with revenues meeting expectations but statutory losses widening. Following these results, analysts maintained revenue forecasts for 2026 but significantly increased loss per share expectations. Despite the higher projected losses, the average price target for AXSM shares was raised, suggesting analysts view the losses as temporary or not detrimental to long-term value.
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock
Axsome Therapeutics COO Mark Jacobson sold 233 shares in the company for approximately $53,165.94, reducing his stake by nearly 5%. This sale occurred as the company reported a Q1 GAAP EPS miss, despite a significant 57% year-over-year revenue increase driven by AUVELITY and SUNOSI sales. Despite the stock trading down modestly, analysts have maintained a "Moderate Buy" consensus rating with an average target price of $251.89.
Axsome Therapeutics (AXSM) Q1 Loss Widening To US$64.5 Million Tests Profitability Narratives
Axsome Therapeutics (AXSM) reported a Q1 2026 net loss of US$64.5 million, an increase from previous quarters, despite revenue reaching US$191.2 million. The widening loss raises questions about the company's path to profitability, even as revenue growth and a narrowing trailing twelve-month EPS loss are noted by bullish investors. The stock's high P/S multiple of 16.2x compared to peers and industry, alongside a DCF fair value significantly above its current price, presents mixed valuation signals.
Axsome Therapeutics COO Mark Jacobson sells $1.08m in stock
Axsome Therapeutics COO Mark Jacobson sold common stock worth approximately $1.08 million over two days (May 4-5, 2026), immediately after exercising stock options under a pre-approved trading plan, leaving him with no direct stock holdings. This insider sale comes as Axsome shares trade near their 52-week high, following strong financial results and increased sales guidance for their drug Auvelity, leading several analysts to raise their price targets for the company.
Axsome Therapeutics Reports Strong Q1 2026 Results Driven by Revenue Growth and FDA Approval for AUVELITY
Axsome Therapeutics announced strong first-quarter 2026 results, with total revenue from its commercial products increasing by 57% year-over-year to $191 million, primarily driven by AUVELITY and SUNOSI. The company also secured FDA approval for AUVELITY to treat agitation associated with Alzheimer's disease, marking its second FDA breakthrough therapy designation and priority review for the drug. Additionally, Axsome expanded its sales force, submitted a New Drug Application for AXS-12, and advanced its pipeline with AXS-20 entering Phase III development.
Strong Drug Sales Lift Axsome Revenue, But Profit Miss Drags Stock
Axsome Therapeutics (NASDAQ: AXSM) saw its shares fall after reporting a wider first-quarter loss of $1.26 per share, missing analyst expectations despite stronger-than-expected total net product revenue of $191.2 million, a 57% increase year-over-year. The revenue growth was primarily driven by strong sales of Auvelity, which jumped 59% to $153.2 million, and the company also advanced its pipeline with FDA approval for Auvelity's new indication and a new drug application for AXS-12. Despite an overbought RSI, the stock maintains a strong uptrend, trading above its 20-day and 100-day SMAs.
Axsome Therapeutics, Inc. $AXSM Shares Bought by UBS Group AG
UBS Group AG increased its stake in Axsome Therapeutics by 67.2% in Q4 2025, now owning 355,318 shares worth approximately $64.9 million. While institutional investors hold a significant portion of the company, insiders sold shares totaling $11.12 million in the last quarter. Axsome reported strong Q1 2026 revenue of $191.2 million, beating consensus, but missed EPS estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $235.79.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2026 Earnings Call Transcript
Axsome Therapeutics, Inc. (AXSM) reported strong Q1 2026 results, with total revenue reaching $191 million, a 57% year-over-year increase, driven by AUVELITY and SUNOSI. The company recently received FDA approval for AUVELITY to treat agitation associated with Alzheimer's disease, significantly expanding its market potential and leading to an updated peak sales estimate of at least $8 billion annually for the AUVELITY franchise. Axsome is also advancing its pipeline with new product candidates like AXS-12 for narcolepsy and AXS-20 for schizophrenia and Tourette syndrome, alongside ongoing clinical trials for other indications.
Mizuho raises Axsome Therapeutics price target on Auvelity outlook
Mizuho significantly increased its price target for Axsome Therapeutics (NASDAQ:AXSM) to $310 from $228, maintaining an Outperform rating, driven by a 55% surge in Auvelity's projected peak revenue to $5.0 billion by 2038. This optimistic outlook is based on Auvelity's strong performance in depression, promising potential in Alzheimer's disease agitation, and the expansion of Axsome's sales force. The revised target represents about 40% upside potential and aligns with several other analysts who have also raised their price targets for Axsome following strong Q1 2026 earnings and updated peak sales guidance for Auvelity.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics (NASDAQ: AXSM), a biopharmaceutical company specializing in CNS disorders, announced its participation in two upcoming investor conferences in May: the BofA Securities 2026 Health Care Conference and the 2026 RBC Capital Markets Global Healthcare Conference. The company will hold fireside chats at both events, with live webcasts available for investors on its website.
Earnings call transcript: Axsome Therapeutics Q1 2026 misses forecasts
Axsome Therapeutics reported Q1 2026 earnings that missed analyst forecasts for both EPS and revenue, with an EPS of -$1.26 against an expected -$0.83, and revenue of $191.2 million falling short of the $193.46 million estimate. Despite these misses, the company's stock surged over 11% in pre-market trading, driven by the recent FDA approval of Auvelity for Alzheimer’s agitation and robust year-over-year revenue growth of 57%. Axsome provided an updated peak sales outlook for Auvelity, projecting at least $8 billion in annual revenue, equally contributed by its MDD and Alzheimer’s agitation indications.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics, Inc. announced its participation in two upcoming investor conferences in May: the BofA Securities 2026 Health Care Conference and the 2026 RBC Capital Markets Global Healthcare Conference. The company, focused on CNS disorders, will hold fireside chats at both events, with live webcasts available on its investor relations website. Replays will be accessible for approximately 30 days after each event.
Axsome Therapeutics to Participate in Upcoming Investor Conferences
Axsome Therapeutics, a biopharmaceutical company focused on CNS disorders, announced its participation in two upcoming investor conferences in May: the BofA Securities 2026 Health Care Conference and the 2026 RBC Capital Markets Global Healthcare Conference. The company will host fireside chats at both events, with webcasts available on its investor relations website for those unable to attend in person.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages
Axsome Therapeutics (NASDAQ:AXSM) has received an average "Moderate Buy" rating from 21 brokerages, with an average one-year price target of $235.79. The company's Q1 revenue increased 57% year-over-year to $191.2 million, meeting expectations, though GAAP EPS missed estimates at -$1.26. Recent regulatory approvals for AUVELITY and new pipeline additions show potential for future growth.
Mark Jacobson Sells 4,517 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock
Axsome Therapeutics COO Mark Jacobson sold 4,517 shares of company stock for over $1 million, reducing his position by 50%. The sale occurred after the company reported strong revenue growth but missed Q1 EPS estimates, leading to widened losses. Despite the earnings miss, analyst sentiment remains largely positive with multiple price target increases.
Axsome Therapeutics, Inc. 1Q 2026: Revenue $191.2M, EPS $(1.26) — 10-Q Summary
Axsome Therapeutics, Inc. reported its first-quarter 2026 results, showing revenue of $191.2 million, a significant increase from $121.5 million in the prior year. Despite revenue growth, the company posted a net loss of $64.5 million, or diluted EPS of $(1.26), which worsened compared to Q1 2025. The revenue growth was attributed to increased volume of AUVELITY and SUNOSI, as well as the launch of SYMBRAVO, supported by a recent label expansion for AUVELITY and continued R&D efforts.
Oppenheimer raises Axsome Therapeutics price target on Auvelity sales By Investing.com
Oppenheimer has increased its price target for Axsome Therapeutics (NASDAQ:AXSM) to $280 from $250, maintaining an Outperform rating, following strong first-quarter 2026 Auvelity sales of $153.2 million, which exceeded consensus. The company also revised its Auvelity total peak sales guidance to approximately $8 billion from $4 billion. Despite a recent EPS and revenue miss, analysts from Guggenheim and TD Cowen also raised their price targets, reflecting confidence in Axsome's product performance and strategic expansion, including growing its salesforce for major depressive disorder and an upcoming launch for agitation associated with dementia.
Axsome Therapeutics, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:AXSM) 2026-05-04
Axsome Therapeutics, Inc. (AXSM) released its Q1 2026 earnings, reporting an EPS of -$1.26, missing estimates by $0.40, and revenue of $191.20 million, exceeding estimates by $509.10K, which represents a 57.42% year-over-year increase. The company published a slide deck in conjunction with its earnings call.
Axsome Highlights Strong Q1 Growth and AUVELITY Expansion
Axsome Therapeutics reported a strong 57% year-over-year revenue growth in Q1 2026, reaching $191.2 million, primarily driven by AUVELITY sales. Despite this growth, the company posted a net loss of $64.5 million due to increased R&D and commercialization spending. Key developments include the FDA approval of AUVELITY for Alzheimer's agitation, expansion of sales forces, and advancement of its CNS pipeline, positioning Axsome for future growth in central nervous system therapeutics.
Axsome Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Axsome Therapeutics reported strong first quarter 2026 financial results, with total net product revenue reaching $191.2 million, a 57% year-over-year increase. The company announced the FDA approval of AUVELITY for agitation associated with Alzheimer’s disease dementia and submitted an NDA for AXS-12 for
Axsome Therapeutics (NASDAQ: AXSM) posts 57% Q1 revenue growth to $191M
Axsome Therapeutics reported Q1 2026 total net product revenue of $191.2 million, a 57% increase year-over-year, driven by strong growth in AUVELITY and SUNOSI sales. Despite this revenue growth, the company posted a net loss of $64.5 million due to increased operating expenses for commercial expansion and R&D. Axsome also announced FDA approval for AUVELITY to treat agitation associated with Alzheimer’s disease and continues to advance a broad late-stage neuroscience pipeline.
Axsome Therapeutics (AXSM) Is Up 11.1% After FDA Clears AUVELITY For Alzheimer’s Agitation Treatment
Axsome Therapeutics' stock rose 11.1% after the FDA approved AUVELITY for treating agitation associated with Alzheimer’s disease. This approval broadens AUVELITY's market beyond major depressive disorder into a significant, underserved patient population, supported by strong clinical data. The expansion is expected to impact Axsome's long-term financial outlook, though investors will monitor the balance between increased revenue and rising operating costs.
Vanguard Group Inc. Sells 15,828 Shares of Axsome Therapeutics, Inc. $AXSM
Vanguard Group Inc. reduced its stake in Axsome Therapeutics (NASDAQ:AXSM) by 0.4% in the fourth quarter of 2026, selling 15,828 shares but still owning 4,164,818 shares valued at approximately $760.7 million. Despite institutional selling, FDA approval of AUVELITY for agitation associated with Alzheimer’s dementia has led to increased analyst support, with price targets raised by Needham and UBS. However, company insiders, including the COO and a director, have also been selling shares, cumulatively disposing of 100,288 shares worth over $17 million in the past 90 days.
Axsome Wins FDA Nod For Expanded Use For Auvelity Beyond Depression
The FDA has approved Axsome Therapeutics' Auvelity for agitation related to Alzheimer's disease, marking a significant expansion beyond its current major depressive disorder indication. This approval is based on positive Phase 3 trial data showing improved agitation symptoms and longer time to relapse. Analysts project substantial peak sales for Auvelity in this new indication, given the largely underserved market.
Axsome Therapeutics Wins FDA Nod for Auvelity in Alzheimer’s Agitation, Launch Set for June
Axsome Therapeutics has received FDA approval for Auvelity to treat agitation associated with dementia due to Alzheimer's disease, expanding its indication beyond major depressive disorder. The company plans a full commercial launch in June, targeting a large market with an expanded sales team and anticipating broad payer coverage. Clinical trials demonstrated Auvelity's rapid and durable efficacy, with a low discontinuation rate, offering a new treatment option for a significant unmet medical need.
Axsome Drug’s FDA Approval Unlocks New Opportunity in Alzheimer’s Agitation
Axsome Therapeutics' drug Auvelity has received FDA approval to treat agitation associated with dementia due to Alzheimer's disease, making it only the second drug approved for this specific indication. Previously approved for major depressive disorder, Auvelity offers a safety advantage over the other approved treatment, Rexulti, which carries a black box warning for increased mortality risk in elderly dementia patients. This new approval positions Auvelity as a potential first-line treatment and could open up a significant market opportunity for Axsome, with peak sales projected to reach over $2.1 billion for this indication alone.
